一种基于pullulan的双层膜,用于口腔输送GLP-1类同类物
Sandeep Karki1, Sahil Malhotra1, Muhammad Ijaz1
1UCD School of Veterinary Medicine and Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
Carbohydrate polymers
|March 14, 2026
概括
基于Pullulan的膜可以增强口腔的输送. 一种类似葡萄糖素的-1受体激动剂 (GLP-1 RA) 和透增强剂,糖解氧酸盐 (GDC),被纳入了pullulan膜中,通过口腔路线改善了的生物利用性.
科学领域:
- 制药科学 制药科学
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
背景情况:
- 口腔途径为递送提供了一个非注射替代方案,但面临着低生物可用性的挑战.
- 需要新的配方策略来克服这些局限性,并通过口腔粘膜改善的吸收.
研究的目的:
- 开发和评估基于pullulan的双层膜,用于同时提供一种类似葡萄糖类-1受体激动剂 (GLP-1 RA) 的模型模拟物和一种表皮膜透增强剂糖解氧酸盐 (GDC).
- 从开发的膜中评估GLP-1RA的物理化学特性和ex vivo口腔透.
主要方法:
- 比莱尔薄膜是使用普鲁兰-碳基甲基纤维素粘膜粘合层和氨基甲基烯酸盐共聚合物支持层制造的.
- 进行了薄膜的物理化学表征,以确认其适用于口腔应用.
- 在山顶室中使用猪口腔粘膜进行了ex vivo透研究,以确定最佳的GLP-1 RA:GDC比率并评估薄膜性能.
主要成果:
- 确定了最佳的GLP-1 RA:GDC比率 (约为1:2),在200mM GDC的情况下,在3小时内达到~6%的流量.
- 基于Pullulan的薄膜成功地结合了GLP-1 RA和GDC,在体外口腔粘膜中实现了显著的流 (单层薄膜约4.5%,双层薄膜在3小时后约2%).
- 没有观察到明显的组织损伤,表明配方具有良好的生物相容性.
结论:
- 基于Pullulan的双层膜代表了增强口腔递送的有希望的平台.
- 在pullulan膜中与GDC同时使用GLP-1 RA提供了一种可行的策略,通过非可注射口腔途径改善的生物可用性.
- 这种基于碳水化合物聚合物的方法有可能发展出先进的口服疗法.
更多相关视频
04:28Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
13.3K
04:09Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel FilmWound Healing
Published on: December 13, 2024
1.4K
相关概念视频
01:26Oral Drug Delivery Systems: Continuous-Release Systems
135
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
135
01:11Oral Drug Delivery Systems: Delayed-Release Systems
96
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
96
01:18Drug Delivery: Enteral Route
2.3K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
2.3K
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
76
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
76
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
296
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
296